File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Regression of liver fibrosis after HBsAg loss: a prospective matched case-control evaluation using transient elastography and serum Enhanced Liver Fibrosis (ELF) test

TitleRegression of liver fibrosis after HBsAg loss: a prospective matched case-control evaluation using transient elastography and serum Enhanced Liver Fibrosis (ELF) test
Authors
Issue Date2021
PublisherSpringer (India) Private Ltd. The Journal's web site is located at http://www.springer.com/medicine/internal/journal/12072
Citation
The 30th Asian Pacific Association for The Study of Liver (APASL) 2021, Virtual Meeting, Bangkok, Thailand, 4-6 February 2021. In Hepatology International, 2021, v. 15 n. Suppl. 1, p. S1 How to Cite?
AbstractBackground: We assessed the effect of hepatitis B surface antigen (HBsAg) seroclearance on liver fibrosis regression in patients with chronic hepatitis B (CHB). Method: CHB patients with recent spontaneous HBsAg seroclearance (cases) were age- and gender- matched with treatment-naïve HBeAg-negative CHB infection (controls). Paired transient elastography (TE) and Enhanced Liver Fibrosis (ELF) measurements were performed at baseline and 3-year. Fibrosis progression and regression were defined as increase and decrease in ≥1 fibrosis stage, respectively. Results: In this interim analysis, 40 cases and 142 controls were recruited [median age 55.6 (interquartile range, IQR 49.8-60.9), 53.8% male]. The median liver stiffness (LS) values were similar between the two groups at baseline (5.4 vs. 5.2 kPa, P=0.765) and at 3-years (5.9 vs. 5.5 kPa, P=0.455) respectively. The baseline controlled attenuation parameter values were significantly higher in cases vs controls (288 vs 251 dB/m, respectively, P=0.001). The median ELF at 3-year was significantly higher than baseline in the controls (8.6 vs. 8.4, P=0.033). All patients with severe steatosis had significantly higher baseline LS (5.9 vs. 4.8 kPa; P<0.001), 3-year LS (6.4 vs 5.2 kPa; P<0.001), and baseline ELF (8.8 vs. 8.3, P=0.028). The proportion of patients with fibrosis progression (25.6% vs. 15.5%, respectively, P=0.111) and regression (10.3% vs. 14.8%, P=0.604) was similar in cases vs controls. Conclusion: Over a period of 3 years, fibrosis regression and progression were observed at a similar rate in patients with HBsAg seroclearance compared to patients with inactive CHB. Severe hepatic steatosis was associated with higher LS and ELF. Grant support: Health and Medical Research Fund, Food and Health Bureau, The Government of the Hong Kong Special Administrative Region, The People's Republic of China (HMRF project number: 16171251)
DescriptionYIA: Acute Liver Failure and Artificial Liver Support - no. 1
Persistent Identifierhttp://hdl.handle.net/10722/300708
ISSN
2023 Impact Factor: 5.9
2023 SCImago Journal Rankings: 1.813

 

DC FieldValueLanguage
dc.contributor.authorMak, LY-
dc.contributor.authorWong, DKH-
dc.contributor.authorHui, WHR-
dc.contributor.authorCheung, KSM-
dc.contributor.authorLiu, F-
dc.contributor.authorFung, JYY-
dc.contributor.authorSeto, WKW-
dc.contributor.authorYuen, RMF-
dc.date.accessioned2021-06-18T14:55:55Z-
dc.date.available2021-06-18T14:55:55Z-
dc.date.issued2021-
dc.identifier.citationThe 30th Asian Pacific Association for The Study of Liver (APASL) 2021, Virtual Meeting, Bangkok, Thailand, 4-6 February 2021. In Hepatology International, 2021, v. 15 n. Suppl. 1, p. S1-
dc.identifier.issn1936-0533-
dc.identifier.urihttp://hdl.handle.net/10722/300708-
dc.descriptionYIA: Acute Liver Failure and Artificial Liver Support - no. 1-
dc.description.abstractBackground: We assessed the effect of hepatitis B surface antigen (HBsAg) seroclearance on liver fibrosis regression in patients with chronic hepatitis B (CHB). Method: CHB patients with recent spontaneous HBsAg seroclearance (cases) were age- and gender- matched with treatment-naïve HBeAg-negative CHB infection (controls). Paired transient elastography (TE) and Enhanced Liver Fibrosis (ELF) measurements were performed at baseline and 3-year. Fibrosis progression and regression were defined as increase and decrease in ≥1 fibrosis stage, respectively. Results: In this interim analysis, 40 cases and 142 controls were recruited [median age 55.6 (interquartile range, IQR 49.8-60.9), 53.8% male]. The median liver stiffness (LS) values were similar between the two groups at baseline (5.4 vs. 5.2 kPa, P=0.765) and at 3-years (5.9 vs. 5.5 kPa, P=0.455) respectively. The baseline controlled attenuation parameter values were significantly higher in cases vs controls (288 vs 251 dB/m, respectively, P=0.001). The median ELF at 3-year was significantly higher than baseline in the controls (8.6 vs. 8.4, P=0.033). All patients with severe steatosis had significantly higher baseline LS (5.9 vs. 4.8 kPa; P<0.001), 3-year LS (6.4 vs 5.2 kPa; P<0.001), and baseline ELF (8.8 vs. 8.3, P=0.028). The proportion of patients with fibrosis progression (25.6% vs. 15.5%, respectively, P=0.111) and regression (10.3% vs. 14.8%, P=0.604) was similar in cases vs controls. Conclusion: Over a period of 3 years, fibrosis regression and progression were observed at a similar rate in patients with HBsAg seroclearance compared to patients with inactive CHB. Severe hepatic steatosis was associated with higher LS and ELF. Grant support: Health and Medical Research Fund, Food and Health Bureau, The Government of the Hong Kong Special Administrative Region, The People's Republic of China (HMRF project number: 16171251)-
dc.languageeng-
dc.publisherSpringer (India) Private Ltd. The Journal's web site is located at http://www.springer.com/medicine/internal/journal/12072-
dc.relation.ispartofHepatology International-
dc.relation.ispartofThe 30th Asian Pacific Association for the Study of Liver (APASL) Annual Meeting, 2021-
dc.titleRegression of liver fibrosis after HBsAg loss: a prospective matched case-control evaluation using transient elastography and serum Enhanced Liver Fibrosis (ELF) test-
dc.typeConference_Paper-
dc.identifier.emailMak, LY: lungyi@hku.hk-
dc.identifier.emailWong, DKH: danywong@hku.hk-
dc.identifier.emailHui, WHR: huirex@connect.hku.hk-
dc.identifier.emailCheung, KSM: cks634@hku.hk-
dc.identifier.emailFung, JYY: jfung@hkucc.hku.hk-
dc.identifier.emailSeto, WKW: wkseto@hku.hk-
dc.identifier.emailYuen, RMF: mfyuen@hku.hk-
dc.identifier.authorityMak, LY=rp02668-
dc.identifier.authorityWong, DKH=rp00492-
dc.identifier.authorityCheung, KSM=rp02532-
dc.identifier.authorityFung, JYY=rp00518-
dc.identifier.authoritySeto, WKW=rp01659-
dc.identifier.authorityYuen, RMF=rp00479-
dc.description.natureabstract-
dc.identifier.hkuros322882-
dc.identifier.volume15-
dc.identifier.issueSuppl. 1-
dc.identifier.spageS1-
dc.identifier.epageS1-
dc.publisher.placeIndia-
dc.identifier.partofdoi10.1007/s12072-021-10213-7-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats